Total Funding
30
40
Total FundingGrant raised
Growth Score
-2 pts
Heat Score
-16 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
106058
Dialectic Therapeutics is a biotechnology company focused on creating innovative new technologies to end cancer.
- John Harkey: Co-Founder
- David Genecov: President and CEO, Co-Founder
About the Company
Dialectic Therapeutics (DT) is a pre-clinical biotechnology company dedicated to the development of unique, impactful anti-cancer drugs that effectively treat patients with few to no other options. The company's drugs selectively induce cancer cells to degrade B-cell lymphoma and stimulate the cells to commit suicide or become susceptible to
chemotherapy, enabling patients to have increased disease-free survival.
Dialectic Therapeutics was founded in 2018 and is located in Dallas, Texas.
